This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment is featured in this month's Men's Health Magazine.
First launched last summer for iPhone, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses a device’s camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the smartphone’s GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical diagnosis and treatment.
“Being currently used in nearly 50 countries, and having been named one of the ‘Top 10 Apps That Could Save Your Life’
in a recent issue of Parade Magazine, MelApp has become a worldwide success,” stated Stephen D. Barnhill, M.D. Chairman and CEO of Health Discovery Corporation. “We are very proud of the fact that we continue to hear from people who have used MelApp and as a result they have made appointments with their physicians to have a proper medical examination and biopsy which led to a diagnosis of early melanoma still in the curable stage. This demonstrates the importance of MelApp in educating the public about melanoma.”
Now available for iPhone, iPod touch, and iPad, as well as for Android, MelApp is available for download at a special price of $1.99. For more complete details, visit
Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.